Celldex Therapeutics, Inc. $CLDX Shares Sold by Commodore Capital LP

Commodore Capital LP reduced its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 15.3% in the 4th quarter, Holdings Channel reports. The institutional investor owned 2,565,000 shares of the biopharmaceutical company’s stock after selling 463,335 shares during the period. Celldex Therapeutics accounts for 4.6% of Commodore Capital LP’s investment portfolio, making the stock its 8th biggest holding. Commodore Capital LP’s holdings in Celldex Therapeutics were worth $69,665,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Segall Bryant & Hamill LLC grew its stake in shares of Celldex Therapeutics by 36.3% during the third quarter. Segall Bryant & Hamill LLC now owns 528,597 shares of the biopharmaceutical company’s stock worth $13,675,000 after purchasing an additional 140,709 shares during the period. Eventide Asset Management LLC grew its stake in shares of Celldex Therapeutics by 37.1% during the third quarter. Eventide Asset Management LLC now owns 1,859,095 shares of the biopharmaceutical company’s stock worth $48,096,000 after purchasing an additional 502,909 shares during the period. American Century Companies Inc. grew its stake in shares of Celldex Therapeutics by 4.6% during the third quarter. American Century Companies Inc. now owns 815,560 shares of the biopharmaceutical company’s stock worth $21,099,000 after purchasing an additional 35,575 shares during the period. Propel Bio Management LLC acquired a new stake in shares of Celldex Therapeutics during the third quarter worth $4,010,000. Finally, Braidwell LP acquired a new stake in shares of Celldex Therapeutics during the third quarter worth $15,307,000.

Celldex Therapeutics Trading Up 1.9%

NASDAQ:CLDX opened at $32.93 on Thursday. Celldex Therapeutics, Inc. has a 1 year low of $19.52 and a 1 year high of $35.79. The stock has a market cap of $2.58 billion, a price-to-earnings ratio of -7.73 and a beta of 0.95. The stock has a 50-day moving average price of $31.96 and a two-hundred day moving average price of $28.97.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.03). The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.80 million. Sell-side analysts forecast that Celldex Therapeutics, Inc. will post -4.36 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on CLDX. Stifel Nicolaus reaffirmed a “buy” rating and set a $68.00 price objective (up from $58.00) on shares of Celldex Therapeutics in a research note on Thursday, February 26th. Wolfe Research raised Celldex Therapeutics from a “peer perform” rating to an “outperform” rating and set a $44.00 price objective for the company in a research note on Monday, March 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Monday, April 20th. Wells Fargo & Company lifted their price objective on Celldex Therapeutics from $38.00 to $54.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 13th. Finally, The Goldman Sachs Group lifted their price objective on Celldex Therapeutics from $30.00 to $34.00 and gave the stock a “neutral” rating in a research note on Monday, March 2nd. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Celldex Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $49.30.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.